to infusing albumin by physician who treated him before the admission. So, actually pleural effusion seemed to be transudative.
Contrast-enhanced computed tomography of the chest and abdomen revealed lymph node edema of <1 cm in the bilateral axilla and mediastinum.
A right axillary lymph node biopsy was normal and laboratory tests revealed mildly elevated levels of interleukin-6 at 25.2 pg/mL, vascular endothelial growth factor (VEGF) at 179 pg/mL, gamma globulin at 0.91 g/dL, CRP at 2.3 mg/dL, and IgG4 at 48.0 mg/dL (Table 1) ; thus, Castleman disease was ruled out. Serum positivity for anti-SS-A and anti-SS-B antibodies (Table 1) , as well as an ocular staining score of >4 points in both eyes, indicated that the subject satisfied 2 out of 3 items of the 2012 classification for Sjögren's syndrome established by the American College of Rheumatology and The Sjögren's International Collaborative Clinical Alliance; thus, the patient was diagnosed with Sjögren's syndrome. 2 Furthermore, gum test revealed dry mouth, with a saliva flow rate of 0.5 mL/10 min.
Biopsies of the stomach, duodenum, rectum, skin, abdominal wall fat, and bone marrow were performed; however, since amyloid deposition was not observed, amyloidosis was ruled out. Biopsies of the stomach and duodenum showed only mild lymphangiectasis. Immunologic studies to assess complements were not performed.
Fecal fat staining was negative. However, technetium-99 m-labeled human serum albumin scintigraphy revealed early radioisotope accumulation in the small bowel ( Figure 1 ). Because of this typical finding of protein-losing gastroenteropathy and absence of gastrointestinal bleeding, we diagnosed protein-losing gastroenteropathy.
Fecal alpha-1-antitrypsin test was useful but unavailable at our hospital.
| OUTCOME
On day 18 of hospitalization, a dose of prednisolone at 30 mg/d (0.5 mg/kg/d) was initiated. On day 24, a sudden drop in blood pressure, reduced level of consciousness, elevated level of hematocrit (Ht) at 48.3%, pleural effusion with ascites, pericardial effusion, systemic edema and decreased level of serum albumin at 1.7 g/dL were observed. This led to a suspicion of protein leakage from a location other than the gastrointestinal tract, and upon diagnosis of secondary systemic capillary leak syndrome, 3 human gamma globulin at a dose of 0.4 g/kg/d was administered for 5 days. Because the improvement in edema was poor, the dosage of prednisolone was increased to 50 mg/d starting on day 16; however, the patient showed little response to this increase in dosage of prednisolone. From day 28 to day 30, steroid pulse therapy was administered with methylprednisolone at 1 g/d and theophylline therapy was simultaneously initiated and maintained at a serum concentration of 10-20 μg/mL. On day 31, his body weight reached its maximum value of 71.2 kg (9.0 kg increase since admission), and prednisolone was recommenced at 50 mg/day. From day 32 to day 42, 20% albumin at 100 mL/d and furosemide at 20 mg/d were administered. As a result, his body weight gradually decreased and the edema also improved. On day 45, theophylline was discontinued, and the dosage of prednisolone was reduced on days 46, 61, and 75 to 40 mg/d, 30 mg/d, and 25 mg/d, respectively. On day 80, he was discharged from the hospital, and he subsequently continues to receive treatment on an outpatient basis.
T A B L E 1 Blood tests results

Initial
| DISCUSSION
Autoimmume diseases that cause protein-losing gastroenteropathy include scleroderma, systemic lupus erythematosus, Sjögren's syndrome, rheumatoid arthritis, mixed connective tissue disease, and dermatomyositis, and the cause of proteinlosing gastroenteropathy associated with autoimmune disease is thought to be related to capillary hyperpermeability. 1 Among autoimmune diseases, there have been 21 published reports from 1988 to 2017 in English and Japanese of cases presenting with Sjögren's syndrome concurrent with proteinlosing gastroenteropathy, as in the present case (Table 2 ).
1, 4-23 Among such publications, there are no reports of secondary systemic capillary leak syndrome, thereby making our case the first case to be reported. Among the 21 reported cases, 18 were females and 19 were reported from East Asia. The present case is also considered a rare case, as the patient is elderly and male. Among the 21 patients reported, 20 received prednisolone, and in the event of a poor response to steroids, additional treatment was administered (eg, cyclophosphamide, hydroxychloroquine, mizoribine, and rituximab), resulting in the alleviation of symptoms in all patients.
In the present case, a sudden drop in blood pressure and hemoconcentration were observed on day 24. Moreover, pleural effusion with ascites, pericardial effusion, and systemic edema were observed. Thus, protein leak other than that from the gastrointestinal tract was suspected, leading to the diagnosis of secondary systemic capillary leak syndrome.
Systemic capillary leak syndrome is a rare disease characterized by 3 features, comprising hypotension, hypoalbuminemia, and hemoconcentration, and is said to cause disruption of vascular endothelial cells, resulting in the leakage of plasma proteins into the interstitial compartment. Because of normal blood pressure and no sign of hemoconcentration on admission, systemic capillary leak syndrome did not present on admission.
The involvement of VEGF has been suggested in the extravascular leakage of protein associated with systemic capillary leak syndrome. Moreover, because our patient also presented with elevated levels of VEGF, VEGF appears to be involved. There has been a reported case of systemic capillary leak syndrome treated with high-dose intravenous immunoglobulin therapy (IVIG), theophylline therapy (blood concentration at 15-25 μg/mL), terbutaline (beta-2 receptor agonist), anti-human-TNF-alpha monoclonal antibodies, and anti-VEGF antibodies. 3 Although our patient was first treated with prednisolone at a dose of 30 mg/d for protein-losing gastroenteropathy, he later developed secondary systemic capillary leak syndrome, and thus IVIG was administered at a dose of 0.4 g/ kg for 5 days, a regimen that is also considered to be a valid treatment for Sjögren's syndrome. Upon completion of IVIG therapy, there was no clear therapeutic effect, and additional treatment with steroid pule therapy and theophylline therapy were administered, which successfully alleviated the symptoms. However, it is unclear whether the steroid, IVIG, or theophylline therapy was effective.
In conclusion, we report the case of a patient who presented with Sjögren's syndrome concurrent with proteinlosing gastroenteropathy and whose condition became severe upon developing secondary systemic capillary leak syndrome. However, the patient's condition was immediately identified, and he recovered with the simultaneous administration of treatment for Sjögren's syndrome and systemic capillary leak syndrome.
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